2025-07-21 14:26Summary of Key Points from the Conference Call Industry Overview - Industry: Biopharma in North America - Market Analysis: Comprehensive analysis of the US drug market conducted by IQVIA Rx Key Market Metrics - Total Prescription Year-over-Year (YoY) Growth: - Latest weekly growth (week ending July 11, 2025) was +4.0%, up from +3.4% the previous week and +2.5% over the past 12 weeks [1][6] - For the week ended July 11, the total market weekly TRx YoY change was +4.0%, compared to +1.8% a year ago [2] Prescription Trends - Rolling 4-week TRx YoY: +3.0% - Rolling 12-week TRx YoY: +2.5% - Extended Unit (EUTRx) Weekly YoY Growth: +3.3%, which is below the TRx YoY [2] - Sequential Weekly TRx Growth: +12.0%, a significant increase compared to -7.3% the week before [2] Company-Specific Insights - Bristol Myers Squibb (BMY): - Cobenfy approved for schizophrenia on September 26, 2024, with scripts at ~2,040 for the week, up from ~1,820 the previous week [3] - To meet 2025 consensus expectations, Cobenfy TRx needs to track at ~2-3x the volumes from recent schizophrenia launches [3] - Vertex Pharmaceuticals (VRTX): - Journavx approved for acute pain on January 30, 2025, with scripts at ~5,880 for the week, up from ~5,180 the previous week [4] - Hospital scripts, which are not captured by IQVIA, account for ~28% of total scripts [4] - Gilead Sciences (GILD): - Yeztugo approved on June 18, 2025, with latest week TRx at ~70, up from ~20 the previous week [5] - Yeztugo's injectable formulation accounted for 54% of total TRx [5] Competitive Landscape - Launch Comparisons: - GILD's Yeztugo compared to Descovy and Apretude [5] - BMY's Sotyktu launch tracked against AMGN's Otezla [9] - LLY's Kisunla launched in July 2024 for Alzheimer's [9] Pricing and Sales Analysis - Immunology Pricing: Updated charts for 2Q25 for Stelara and Tremfya, analyzing how additional indications impact price per script [10] - Biosimilar Adoption: Comprehensive analysis of biosimilars across various branded drugs [12] Notable Trends - Seasonal Respiratory Vaccine Tracking: Exhibits tracking RSV and COVID vaccine weekly and monthly TRx launch trends [11] - Key Products Performance: Detailed tracking of TRx market share and performance for major pharmaceutical companies [48] Conclusion - The biopharma industry in North America is experiencing positive growth in total prescriptions, with significant contributions from new product launches and competitive dynamics among major players. The analysis indicates a robust market environment with potential investment opportunities in emerging therapies and established products.